After 2 years of the COVID-19 pandemic, the Annual Meeting of the American Society of Clinical Oncology(ASCO), held in Chicago, USA, and virtually from 3rd–7th June, 2022 saw leading experts from around the world gather again to further discuss the most exciting updates in the field of lung cancer. Impressively, under the motto “discoveries are nice, but validation is what moves science forward” we saw a therapeutically concept circle closing for patients with resectable stage IIIA-B non-small-cell lung cancer, improved overall survival due to the incorporation of immunotherapy in unresectable stage III NSCLC and new ways to improve patient outcomes by explicitly targeting KRASG12C, METex14, EGFR and ALK. For those patients who do not harbor genomic alterations, anti-PD-(L)1 antibodies with or without chemotherapy as well as combinations of immune checkpoint inhibitors with other drug classes are outlined. Even in the refractory setting of patients with stage IV or recurrent, previously treated NSCLC a synergistic benefit of immunotherapy plus an anti-VEGFR-2 antibody in the immune checkpoint inhibitor refractory setting was presented as well as successful and less successful combination strategies in the treatment of extensive-stage small-cell lung cancer.

As an additional feature, you willfind expert video interviews with John Varlotto and Jessica Donington on different conference highlights on our website. 

Download the report, or visit memo inOncology 

Access an article directly (English):

Preface

Early-stage NSCLC: perioperative strategies and approaches in the unresectable

Targeting KRASG12C, METex14, EGFR & ALK: new ways to further improve patient outcomes

Deeper insights into combinations of immune checkpoint inhibitors with other drug classes

Extensive-stage small-cell lung cancer: successful and less successful combination strategies

Full Report (English)